Skip navigation
University library of Heidelberg
Availability: reference only

Verfügbarkeit
Location: ---
Copies: ---
heiBIB
 Online resource
Verfasst von:Simovic, Milena [VerfasserIn]   i
 Bolkestein, Michiel [VerfasserIn]   i
 Moustafa, Mahmoud [VerfasserIn]   i
 Wong, John K. L. [VerfasserIn]   i
 Körber, Verena [VerfasserIn]   i
 Benedetto, Sarah [VerfasserIn]   i
 Khalid, Umar [VerfasserIn]   i
 Schreiber, Hannah [VerfasserIn]   i
 Jugold, Manfred [VerfasserIn]   i
 Korshunov, Andrey [VerfasserIn]   i
 Hübschmann, Daniel [VerfasserIn]   i
 Mack, Norman [VerfasserIn]   i
 Brons, Stephan [VerfasserIn]   i
 Wei, Pei-Chi [VerfasserIn]   i
 Breckwoldt, Michael O. [VerfasserIn]   i
 Heiland, Sabine [VerfasserIn]   i
 Bendszus, Martin [VerfasserIn]   i
 Debus, Jürgen [VerfasserIn]   i
 Höfer, Thomas [VerfasserIn]   i
 Zapatka, Marc [VerfasserIn]   i
 Kool, Marcel [VerfasserIn]   i
 Pfister, Stefan [VerfasserIn]   i
 Abdollahi, Amir [VerfasserIn]   i
 Ernst, Aurélie [VerfasserIn]   i
Titel:Carbon ion radiotherapy eradicates medulloblastomas with chromothripsis in an orthotopic Li-Fraumeni patient-derived mouse model
Verf.angabe:Milena Simovic, Michiel Bolkestein, Mahmoud Moustafa, John K L Wong, Verena Körber, Sarah Benedetto, Umar Khalid, Hannah Sophia Schreiber, Manfred Jugold, Andrey Korshunov, Daniel Hübschmann, Norman Mack, Stephan Brons, Pei-Chi Wei, Michael O Breckwoldt, Sabine Heiland, Martin Bendszus, Jürgen Debus, Thomas Höfer, Marc Zapatka, Marcel Kool, Stefan M Pfister, Amir Abdollahi, and Aurélie Ernst
E-Jahr:2021
Jahr:28 May 2021
Umfang:14 S.
Fussnoten:Gesehen am 13.12.2022
Titel Quelle:Enthalten in: Neuro-Oncology
Ort Quelle:Oxford : Oxford Univ. Press, 1999
Jahr Quelle:2021
Band/Heft Quelle:23(2021), 12, Seite 2028-2041
ISSN Quelle:1523-5866
Abstract:Medulloblastomas with chromothripsis developing in children with Li-Fraumeni Syndrome (germline TP53 mutations) are highly aggressive brain tumors with dismal prognosis. Conventional photon radiotherapy and DNA-damaging chemotherapy are not successful for these patients and raise the risk of secondary malignancies. We hypothesized that the pronounced homologous recombination deficiency in these tumors might offer vulnerabilities that can be therapeutically utilized in combination with high linear energy transfer carbon ion radiotherapy. We tested high-precision particle therapy with carbon ions and protons as well as topotecan with or without PARP inhibitor in orthotopic primary and matched relapsed patient-derived xenograft models. Tumor and normal tissue underwent longitudinal morphological MRI, cellular (markers of neurogenesis and DNA damage-repair), and molecular characterization (whole-genome sequencing).In the primary medulloblastoma model, carbon ions led to complete response in 79% of animals irrespective of PARP inhibitor within a follow-up period of 300 days postirradiation, as detected by MRI and histology. No sign of neurologic symptoms, impairment of neurogenesis or in-field carcinogenesis was detected in repair-deficient host mice. PARP inhibitors further enhanced the effect of proton irradiation. In the postradiotherapy relapsed tumor model, median survival was significantly increased after carbon ions (96 days) versus control (43 days, P < .0001). No major change in the clonal composition was detected in the relapsed model. The high efficacy and favorable toxicity profile of carbon ions warrants further investigation in primary medulloblastomas with chromothripsis. Postradiotherapy relapsed medulloblastomas exhibit relative resistance compared to treatment-naïve tumors, calling for exploration of multimodal strategies.
DOI:doi:10.1093/neuonc/noab127
URL:Bibliographic entry. University members only receive access to full-texts for open access or licensed publications.

Volltext: https://doi.org/10.1093/neuonc/noab127
 DOI: https://doi.org/10.1093/neuonc/noab127
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:1826919449
Verknüpfungen:→ Journal

Permanent link to this item:  https://katalog.ub.uni-heidelberg.de/titel/68996691   QR-Code
zum Seitenanfang